Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 16, 2023 to report its fourth quarter and full year 2022 financial results and business highlights.
Related news for (EVLO)
- Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
- Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
- Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
- Evelo Biosciences Closes $25.5 Million Private Placement
- Evelo Biosciences Announces $25.5 Million Private Placement